All In Biotech

Drug Trial Radar · NCT04285086

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

174

Actual

Start

Aug 25, 2020

Primary completion

Nov 12, 2024

Study completion Aug 31, 2029

Sponsor

Lead sponsor
PharmaEssentiaIndustry
Sponsor type
Industry
First posted
Feb 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

Conditions

  • Essential Thrombocythemia

Interventions

  • Ropeginterferon alfa-2bBiological

    Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg

  • AnagrelideDrug

    Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peripheral blood count remissionTime frame: month 9 and month 12
  2. Improvement or non-progression in disease-related signsTime frame: month 9 and month 12
  3. Large symptoms improvement or maintain non-progressionTime frame: month 9 and month 12
  4. Absence of hemorrhagic or thrombotic eventsTime frame: month 9 and month 12

Locations

67 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona

  • Washington University School of Medicine - Division of Oncology

    St Louis, Missouri

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital, Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • NanFang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technolog

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University school of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Ehime University Hospital

    Tōon, Ehime, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • University of Miyazaki Hospital

    Miyazaki, Miyazaki, Japan

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan

  • Kindai University Hospital

    Sayama, Osaka, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Juntendo University Shizuoka Hospital

    Izunokuni, Shizuoka, Japan

  • Juntendo University Hospital

    Bunkyo City, Tokyo, Japan

  • Nippon Medical School Hospital

    Bunkyo City, Tokyo, Japan

  • NTT Medical Center Tokyo

    Shinagawa City, Tokyo, Japan

  • Tokyo Medical University Hospital

    Shinjuku, Tokyo, Japan

  • University of Yamanashi Hospital

    Chūō, Yamanashi, Japan

  • National University Hospital

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • Daegu Catholic University Hospital

    Daegu, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.